Browse files

Dataset

Regulatory T cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors

Dataset ID	Technology	Samples
EGAD00001006415	NextSeq 500	49

Dataset Description

Tregs were sorted as CD4+CD25+CD127- cells from peripheral blood of patients with advanced metastatic melanoma, stage III(B-D)-IV, who were receiving treatment with anti-PD1 (n =26); and patients with kidney, non-small cell lung, liver and bladder cancer who were receiving treatment with anti-PD1. RNA was extracted and polyA libraries were prepared using the Illumina Truseq sample preparation kit v.2. Single-end sequencing was performed on NextSeq500.

Data Use Conditions

See further information on Data Use Conditions

Label	Code	Version	Modifier
general research use	DUO:0000042	2019-01-07

Who controls access to this dataset

For each dataset that requires controlled access, there is a corresponding Data Access Committee (DAC) who determine access permissions. Access to actual data files is not managed by the EGA. If you need to request access to this data set, please contact:

DAC Treg autoimmunity
Contact person: Panayotis Verginis
Email: pverginis [at] bioacademy [dot] gr
More details: EGAC00001001357

Downloads

You don't have access to the download section.

This dataset is featured in 1 study

Studies are experimental investigations of a particular phenomenon. e.g. case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients. Click on one of the Study IDs below to find out more.

Study ID	Study Title	Study Type
EGAS00001004694	Regulatory T cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors	Other

EGA Beacon